Trial · NCT06923280
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HBV DNA and HBsAg undetectable with/without anti-HBs | week 72 | Proportion of patients achieving HBV DNA below the lower limit of quantification (LLOQ; \<20 IU/mL), HBsAg undetectable (\<0.05 IU/mL) (with or without anti-HBs seroconversion), and normal liver biochemical indices at Week 72. |
| Secondary | HBV DNA and HBsAg undetectable with/without anti-HBs during the study | Weeks 24, 48, and 96 | Proportion of patients achieving HBV DNA \<20 IU/mL, HBsAg \<0.05 IU/mL (with or without anti-HBs), and normal liver biochemistry at Weeks 24, 48, and 96. |
| Secondary | HBV DNA and HBsAg undetectable during the study | Weeks 24, 48, 72, and 96 | Proportion of patients achieving HBsAg \<0.05 IU/mL and HBV DNA \<20 IU/mL at Weeks 24, 48, 72, and 96. |
| Secondary | HBsAg level | Weeks 24, 48, 72, and 96 | HBsAg levels in each group at Weeks 24, 48, 72, and 96 |
| Secondary | HBsAg decline from baseline | Weeks 24, 48, 72, and 96 | Magnitude of HBsAg decline from baseline in each group at Weeks 24, 48, 72, and 96 |
| Secondary | HBsAg seroclearance | Weeks 24, 48, 72, and 96 | HBsAg seroclearance rate (HBsAg \<0.05 IU/mL) in each group at Weeks 24, 48, 72, and 96 |
| Secondary | HBsAg seroconversion | Weeks 24, 48, 72, and 96 | HBsAg seroconversion rate (anti-HBs ≥10 mIU/mL) in each group at Weeks 24, 48, 72, and 96 |
| Secondary | HBeAg seroclearance | Weeks 24, 48, 72, and 96 | HBeAg seroclearance rate in baseline HBeAg-positive patients at Weeks 24, 48, 72, and 96 |
| Secondary | HBeAg seroconversion | Weeks 24, 48, 72, and 96 | HBeAg seroconversion rate (anti-HBe positivity) in baseline HBeAg-positive patients at Weeks 24, 48, 72, and 96 |
| Secondary | HBV DNA level | Weeks 24, 48, 72, and 96 | HBV DNA levels in each group at Weeks 24, 48, 72, and 96 |
| Secondary | HBV DNA decline from baseline | Weeks 24, 48, 72, and 96 | Magnitude of HBV DNA decline from baseline in each group at Weeks 24, 48, 72, and 96 |
| Secondary | HBV DNA undetectabe | Weeks 24, 48, 72, and 96 | HBV DNA undetectability rate (\<20 IU/mL) in baseline HBV DNA-positive patients at Weeks 24, 48, 72, and 96 |
| Secondary | ALT levels | Weeks 24, 48, 72, and 96 | ALT levels in each group at Weeks 24, 48, 72, and 96 |
| Secondary | ALT normalization | Weeks 24, 48, 72, and 96 | ALT normalization rate (≤upper limit of normal \[ULN\]) in each group at Weeks 24, 48, 72, and 96 |
| Secondary | ALT levels from baseline | Weeks 24, 48, 72, and 96 | Change in ALT levels from baseline in each group at Weeks 24, 48, 72, and 96 |
| Secondary | saftey | Weeks 24, 48, 72, and 96 | Incidence of adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs) during the study, including findings from Physical examinations, Laboratory tests, Hematology, Urinalysis, Blood biochemistry, Coagulation profile |
| Secondary | Percentage of patients who achieved functional cure | 24 weeks off Peg-IFNα treatment | sustained undetectable HBV DNA and HBsAg loss for at least 24 weeks off Peg-IFNα treatment |
| Other | HBV RNA | Weeks 24, 48, 72, and 96 | HBV pregenomic RNA (pgRNA) levels in each group at Weeks 24, 48, 72, and 96. |
| Other | HBcrAg | Weeks 24, 48, 72, and 96 | HBV core-related antigen (HBcrAg) levels in each group at Weeks 24, 48, 72, and 96 |
| Other | HBsAg-specific T-cell and B-cell | during the study | Longitudinal changes in HBsAg-specific T-cell and B-cell responses during the study |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06923280/registered